| Figures/TablesFigures/Tables | ReferencesReferences
Key points
The neuroendocrine pancreatic tumors are rare tumors, but their incidence is constantly rising.
Even if the management of these tumors has to be surgical as soon as possible, the disease is most often metastatic at the stage of the diagnostic.
The prognostic and the therapeutic options differ from pancreatic adenocarcinoma.
Available treatments have evolved over the last years with recent publications of studies that bring to light the benefits of targeted therapies in this pathology. This has resulted in modifications of both practices and either French and international guidelines.
Therefore, we focus on the management of the grade 1?and grade 2?well-differentiated neuroendocrine pancreatic tumors as classified in new WHO classification of neuroendocrine neoplasms published in 2010.
